Merck's Zetia cuts heart attack, stroke risk in long-awaited study
CHICAGO (Reuters) - After years of uncertainty, a nearly decade-long study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cardiology | Cholesterol | Health | Heart | Heart Attack | Merck | Statin Therapy | Stroke | Study | Zetia